Background: Dalfampridine extended release (DAL) is a broad-spectrum voltage-gated potassium channel blocker that is indicated in multiple sclerosis to improve the nerve conduction of demyelinated axons. Seizures are a known side effect of DAL, which is contraindicated in patients with a history of epilepsy.

Objective: Three cases of multiple sclerosis (MS) with de novo convulsive status epilepticus (CSE) probably related to dalfampridine administration are described.

Methods: No patients had a history of seizures or renal impairment. Biological tests were normal. A brain magnetic resonance imaging (MRI) showed diffuse cortical and subcortical atrophy without active inflammatory lesions.

Results: All three patients presented with CSE that was attributed to DAL and so was discontinued.

Conclusion: These case reports illustrate that, aside from seizures, de novo CSE is a potential complication of MS patients treated with DAL.

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458518790379DOI Listing

Publication Analysis

Top Keywords

multiple sclerosis
12
novo convulsive
8
convulsive status
8
status epilepticus
8
patients history
8
patients
5
epilepticus patients
4
patients multiple
4
sclerosis treated
4
treated dalfampridine
4

Similar Publications

Multiple sclerosis (MS) is a common autoimmune disease that primarily affects young adults. In this condition, the immune system attacks the myelin sheath of nerve cells, leading to a variety of neurological symptoms. MS diagnosis often relies on the analysis of oligoclonal bands (OCBs), which involves detecting oligoclonal immunoglobulin G (IgG) bands in cerebrospinal fluid (CSF) and serum.

View Article and Find Full Text PDF

Single-cell transcriptomics applied to cerebrospinal fluid (CSF) for elucidating the pathophysiology of neurologic diseases has produced only a preliminary characterization of CSF immune cells. CSF derives from and borders central nervous system (CNS) tissue, allowing for comprehensive accounting of cell types along with their relative abundance and immunologic profiles relevant to CNS diseases. Using integration techniques applied to publicly available datasets in combination with our own studies, we generated a compendium with 139 subjects encompassing 135 CSF and 58 blood samples.

View Article and Find Full Text PDF

Brain organoid methodologies to explore mechanisms of disease in progressive multiple sclerosis.

Front Cell Neurosci

December 2024

Department of Clinical Neurosciences and NIHR Biomedical Research Centre, University of Cambridge, Cambridge, United Kingdom.

Multiple sclerosis (MS), a debilitating autoimmune disorder targeting the central nervous system (CNS), is marked by relentless demyelination and inflammation. Clinically, it presents in three distinct forms: relapsing-remitting MS (RRMS), primary progressive MS (PPMS), and secondary progressive MS (SPMS). While disease-modifying therapies (DMTs) offer some relief to people with RRMS, treatment options for progressive MS (pMS) remain frustratingly inadequate.

View Article and Find Full Text PDF

Multiple sclerosis (MS) predominantly affects women of childbearing age, significantly impacting their quality of life (QOL). The diagnosis of MS can influence pregnancy intention, and the level of disability associated with MS may change before and after pregnancy. This study aims to analyze the reproductive characteristics of Iranian female patients with MS (PwMS) and their association with the Expanded Disability Status Scale (EDSS) and pregnancy tendency, providing valuable insights into disease progression and the development of tailored treatments.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!